{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:22:14Z","timestamp":1724804534516},"reference-count":61,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,26]]},"DOI":"10.7759\/cureus.67877","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T06:01:04Z","timestamp":1724738464000},"source":"Crossref","is-referenced-by-count":0,"title":["Maternal Soluble Programmed Death Ligand-1 (sPD-L1) and T-regulatory Cells (Tregs) Alteration in Preeclampsia: A Cross-Sectional Study From Eastern India"],"prefix":"10.7759","author":[{"given":"Prakruti","family":"Dash","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saurav","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharath Kumar","family":"Koppisetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2021.12.001","article-title":"Preeclampsia and eclampsia: the conceptual evolution of a syndrome","volume":"226","author":"Erez O","year":"2022","unstructured":"Erez O, Romero R, Jung E, et al.. Preeclampsia and eclampsia: the conceptual evolution of a syndrome. Am J Obstet Gynecol. 2022, 226:S786-803. 10.1016\/j.ajog.2021.12.001","journal-title":"Am J Obstet Gynecol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.118.313276","article-title":"Preeclampsia: pathophysiology, challenges, and perspectives","volume":"124","author":"Rana S","year":"2019","unstructured":"Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res. 2019, 124:1094-112. 10.1161\/CIRCRESAHA.118.313276","journal-title":"Circ Res"},{"key":"ref3","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han Y","year":"2020","unstructured":"Han Y, Liu D, Li L. PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020, 10:727-42.","journal-title":"Am J Cancer Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13123034","article-title":"Soluble programmed death ligand-1 (sPD-L1): a pool of circulating proteins implicated in health and diseases","volume":"13","author":"Bailly C","year":"2021","unstructured":"Bailly C, Thuru X, Quesnel B. Soluble programmed death ligand-1 (sPD-L1): a pool of circulating proteins implicated in health and diseases. Cancers (Basel). 2021, 13:34. 10.3390\/cancers13123034","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00086","article-title":"Elevated soluble PD-L1 in pregnant women's serum suppresses the immune reaction","volume":"10","author":"Okuyama M","year":"2019","unstructured":"Okuyama M, Mezawa H, Kawai T, Urashima M. Elevated soluble PD-L1 in pregnant women's serum suppresses the immune reaction. Front Immunol. 2019, 10:86. 10.3389\/fimmu.2019.00086","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali DA","year":"2008","unstructured":"Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008, 8:523-32. 10.1038\/nri2343","journal-title":"Nat Rev Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2018.9733","article-title":"Contribution of regulatory T\u00a0cells to immune tolerance and association of microRNA\u2011210 and Foxp3 in preeclampsia","volume":"19","author":"Chen J","year":"2019","unstructured":"Chen J, Zhao L, Wang D, Xu Y, Gao H, Tan W, Wang C. Contribution of regulatory T\u00a0cells to immune tolerance and association of microRNA\u2011210 and Foxp3 in preeclampsia. Mol Med Rep. 2019, 19:1150-8. 10.3892\/mmr.2018.9733","journal-title":"Mol Med Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x20187334","article-title":"PD-1\/PD-L1 regulates Treg differentiation in pregnancy-induced hypertension","volume":"51","author":"Jiang L","year":"2018","unstructured":"Jiang L, Tang C, Gong Y, et al.. PD-1\/PD-L1 regulates Treg differentiation in pregnancy-induced hypertension. Braz J Med Biol Res. 2018, 51:e7334. 10.1590\/1414-431x20187334","journal-title":"Braz J Med Biol Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2017.70","article-title":"The altered PD-1\/PD-L1 pathway delivers the 'one-two punch' effects to promote the Treg\/Th17 imbalance in pre-eclampsia","volume":"15","author":"Zhang Y","year":"2018","unstructured":"Zhang Y, Liu Z, Tian M, Hu X, Wang L, Ji J, Liao A. The altered PD-1\/PD-L1 pathway delivers the 'one-two punch' effects to promote the Treg\/Th17 imbalance in pre-eclampsia. Cell Mol Immunol. 2018, 15:710-23. 10.1038\/cmi.2017.70","journal-title":"Cell Mol Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.806","article-title":"Evaluation of serum lipid profiles, uric acid, and high sensitivity C-reactive protein levels between pregnancy-induced hypertension and normotensive pregnant women attending Ambo University Referral Hospital, Ambo, Ethiopia, 2020: a case-control study","volume":"5","author":"Areda BG","year":"2022","unstructured":"Areda BG, Gizaw ST, Berdida DH, Kebalo AH. Evaluation of serum lipid profiles, uric acid, and high sensitivity C-reactive protein levels between pregnancy-induced hypertension and normotensive pregnant women attending Ambo University Referral Hospital, Ambo, Ethiopia, 2020: a case-control study. Health Sci Rep. 2022, 5:e806. 10.1002\/hsr2.806","journal-title":"Health Sci Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27315","article-title":"The imbalance of Th17\/Treg axis involved in the pathogenesis of preeclampsia","volume":"234","author":"Eghbal-Fard S","year":"2019","unstructured":"Eghbal-Fard S, Yousefi M, Heydarlou H, et al.. The imbalance of Th17\/Treg axis involved in the pathogenesis of preeclampsia. J Cell Physiol. 2019, 234:5106-16. 10.1002\/jcp.27315","journal-title":"J Cell Physiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7150\/jca.57334","article-title":"A snapshot of the PD-1\/PD-L1 pathway","volume":"12","author":"Ghosh C","year":"2021","unstructured":"Ghosh C, Luong G, Sun Y. A snapshot of the PD-1\/PD-L1 pathway. J Cancer. 2021, 12:2735-46. 10.7150\/jca.57334","journal-title":"J Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh M","year":"2009","unstructured":"Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009, 114:1537-44. 10.1182\/blood-2008-12-195792","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00251-017-1015-5","article-title":"PD-1 and cancer: molecular mechanisms and polymorphisms","volume":"70","author":"Salmaninejad A","year":"2018","unstructured":"Salmaninejad A, Khoramshahi V, Azani A, et al.. PD-1 and cancer: molecular mechanisms and polymorphisms. Immunogenetics. 2018, 70:73-86. 10.1007\/s00251-017-1015-5","journal-title":"Immunogenetics"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.562315","article-title":"Response efficacy of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"11","author":"Chen S","year":"2021","unstructured":"Chen S, Zhang Z, Zheng X, et al.. Response efficacy of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. Front Oncol. 2021, 11:10. 10.3389\/fonc.2021.562315","journal-title":"Front Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2016.29","article-title":"Seeing is believing: anti-PD-1\/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy","volume":"1","author":"Tan S","year":"2016","unstructured":"Tan S, Zhang CW, Gao GF. Seeing is believing: anti-PD-1\/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy. Signal Transduct Target Ther. 2016, 1:10. 10.1038\/sigtrans.2016.29","journal-title":"Signal Transduct Target Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.placenta.2010.12.014","article-title":"Review: fetal antigens--identity, origins, and influences on the maternal immune system","volume":"32","author":"Petroff MG","year":"2011","unstructured":"Petroff MG. Review: fetal antigens--identity, origins, and influences on the maternal immune system. Placenta. 2011, 32:S176-81. 10.1016\/j.placenta.2010.12.014","journal-title":"Placenta"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9082536","article-title":"Investigation of the PD-1 and PD-L1 immune checkpoint molecules throughout healthy human pregnancy and in nonpregnant women","volume":"9","author":"Meggyes M","year":"2020","unstructured":"Meggyes M, Nagy DU, Szereday L. Investigation of the PD-1 and PD-L1 immune checkpoint molecules throughout healthy human pregnancy and in nonpregnant women. J Clin Med. 2020, 9:2536. 10.3390\/jcm9082536","journal-title":"J Clin Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002031","article-title":"The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance","volume":"187","author":"D'Addio F","year":"2011","unstructured":"D'Addio F, Riella LV, Mfarrej BG, et al.. The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J Immunol. 2011, 187:4530-41. 10.4049\/jimmunol.1002031","journal-title":"J Immunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/aji.12795","article-title":"Immune checkpoint molecules soluble program death ligand 1 and galectin-9 are increased in pregnancy","volume":"79","author":"Enninga EA","year":"2018","unstructured":"Enninga EA, Harrington SM, Creedon DJ, Ruano R, Markovic SN, Dong H, Dronca RS. Immune checkpoint molecules soluble program death ligand 1 and galectin-9 are increased in pregnancy. Am J Reprod Immunol. 2018, 79:5. 10.1111\/aji.12795","journal-title":"Am J Reprod Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0000000000000305","article-title":"PD-L1 expression in human placentas and gestational trophoblastic diseases","volume":"36","author":"Veras E","year":"2017","unstructured":"Veras E, Kurman RJ, Wang TL, Shih IM. PD-L1 expression in human placentas and gestational trophoblastic diseases. Int J Gynecol Pathol. 2017, 36:146-53. 10.1097\/PGP.0000000000000305","journal-title":"Int J Gynecol Pathol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/aji.13519","article-title":"Soluble PD-L1 and B7-H4 serum levels during the course of physiological pregnancy","volume":"87","author":"Mach P","year":"2022","unstructured":"Mach P, K\u00f6ninger A, Reisch B, Kimmig R, Gellhaus A. Soluble PD-L1 and B7-H4 serum levels during the course of physiological pregnancy. Am J Reprod Immunol. 2022, 87:19. 10.1111\/aji.13519","journal-title":"Am J Reprod Immunol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20030583","article-title":"Involvement of the PD-1\/PD-L1 co-inhibitory pathway in the pathogenesis of the inflammatory stage of early-onset preeclampsia","volume":"20","author":"Meggyes M","year":"2019","unstructured":"Meggyes M, Miko E, Lajko A, et al.. Involvement of the PD-1\/PD-L1 co-inhibitory pathway in the pathogenesis of the inflammatory stage of early-onset preeclampsia. Int J Mol Sci. 2019, 20:583. 10.3390\/ijms20030583","journal-title":"Int J Mol Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jri.2023.103949","article-title":"The programmed cell death protein 1 (PD1) and the programmed cell death ligand 1 (PD-L1) are significantly downregulated on macrophages and Hofbauer cells in the placenta of preeclampsia patients","volume":"157","author":"Mittelberger J","year":"2023","unstructured":"Mittelberger J, Seefried M, L\u00f6b S, et al.. The programmed cell death protein 1 (PD1) and the programmed cell death ligand 1 (PD-L1) are significantly downregulated on macrophages and Hofbauer cells in the placenta of preeclampsia patients. J Reprod Immunol. 2023, 157:49. 10.1016\/j.jri.2023.103949","journal-title":"J Reprod Immunol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00846","article-title":"Immune checkpoint molecules in reproductive immunology","volume":"10","author":"Miko E","year":"2019","unstructured":"Miko E, Meggyes M, Doba K, Barakonyi A, Szereday L. Immune checkpoint molecules in reproductive immunology. Front Immunol. 2019, 10:846. 10.3389\/fimmu.2019.00846","journal-title":"Front Immunol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102376","article-title":"Treg cells in health and autoimmune diseases: new insights from single cell analysis","volume":"110","author":"Scheinecker C","year":"2020","unstructured":"Scheinecker C, G\u00f6schl L, Bonelli M. Treg cells in health and autoimmune diseases: new insights from single cell analysis. J Autoimmun. 2020, 110:10. 10.1016\/j.jaut.2019.102376","journal-title":"J Autoimmun"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-019-00684-7","article-title":"Regulatory T cells: the many faces of Foxp3","volume":"39","author":"Georgiev P","year":"2019","unstructured":"Georgiev P, Charbonnier LM, Chatila TA. Regulatory T cells: the many faces of Foxp3. J Clin Immunol. 2019, 39:623-40. 10.1007\/s10875-019-00684-7","journal-title":"J Clin Immunol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.2010.00836.x","article-title":"The immune system in pregnancy: a unique complexity","volume":"63","author":"Mor G","year":"2010","unstructured":"Mor G, Cardenas I. The immune system in pregnancy: a unique complexity. Am J Reprod Immunol. 2010, 63:425-33. 10.1111\/j.1600-0897.2010.00836.x","journal-title":"Am J Reprod Immunol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/ni1037","article-title":"Regulatory T cells mediate maternal tolerance to the fetus","volume":"5","author":"Aluvihare VR","year":"2004","unstructured":"Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol. 2004, 5:266-71. 10.1038\/ni1037","journal-title":"Nat Immunol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.737862","article-title":"Regulatory T cells in pregnancy adverse outcomes: a systematic review and meta-analysis","volume":"12","author":"Green S","year":"2021","unstructured":"Green S, Politis M, Rallis KS, et al.. Regulatory T cells in pregnancy adverse outcomes: a systematic review and meta-analysis. Front Immunol. 2021, 12:62. 10.3389\/fimmu.2021.737862","journal-title":"Front Immunol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01305","article-title":"Differential dynamics of the maternal immune system in healthy pregnancy and preeclampsia","volume":"10","author":"Han X","year":"2019","unstructured":"Han X, Ghaemi MS, Ando K, et al.. Differential dynamics of the maternal immune system in healthy pregnancy and preeclampsia. Front Immunol. 2019, 10:1305. 10.3389\/fimmu.2019.01305","journal-title":"Front Immunol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901154","article-title":"Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia","volume":"183","author":"Santner-Nanan B","year":"2009","unstructured":"Santner-Nanan B, Peek MJ, Khanam R, Richarts L, Zhu E, Fazekas de St Groth B, Nanan R. Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia. J Immunol. 2009, 183:7023-30. 10.4049\/jimmunol.0901154","journal-title":"J Immunol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2007.03397.x","article-title":"Proportion of peripheral blood and decidual CD4(+) CD25(bright) regulatory T cells in pre-eclampsia","volume":"149","author":"Sasaki Y","year":"2007","unstructured":"Sasaki Y, Darmochwal-Kolarz D, Suzuki D, et al.. Proportion of peripheral blood and decidual CD4(+) CD25(bright) regulatory T cells in pre-eclampsia. Clin Exp Immunol. 2007, 149:139-45. 10.1111\/j.1365-2249.2007.03397.x","journal-title":"Clin Exp Immunol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/aji.12380","article-title":"Prevalence of regulatory T-cell subtypes in preeclampsia","volume":"74","author":"Toldi G","year":"2015","unstructured":"Toldi G, V\u00e1s\u00e1rhelyi ZE, Rig\u00f3 J Jr, et al.. Prevalence of regulatory T-cell subtypes in preeclampsia. Am J Reprod Immunol. 2015, 74:110-5. 10.1111\/aji.12380","journal-title":"Am J Reprod Immunol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms13066548","article-title":"Apoptosis signaling is altered in CD4\u207aCD25\u207aFoxP3\u207a T regulatory lymphocytes in pre-eclampsia","volume":"13","author":"Darmochwal-Kolarz D","year":"2012","unstructured":"Darmochwal-Kolarz D, Saito S, Tabarkiewicz J, Kolarz B, Rolinski J, Leszczynska-Gorzelak B, Oleszczuk J. Apoptosis signaling is altered in CD4\u207aCD25\u207aFoxP3\u207a T regulatory lymphocytes in pre-eclampsia. Int J Mol Sci. 2012, 13:6548-60. 10.3390\/ijms13066548","journal-title":"Int J Mol Sci"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jri.2023.104122","article-title":"Th17 \/ Treg ratio: a prospective study in a group of pregnant women with preeclampsia and fetal growth restriction","volume":"159","author":"Braga A","year":"2023","unstructured":"Braga A, Neves E, Guimar\u00e3es J, Braga J, Vasconcelos C. Th17 \/ Treg ratio: a prospective study in a group of pregnant women with preeclampsia and fetal growth restriction. J Reprod Immunol. 2023, 159:122. 10.1016\/j.jri.2023.104122","journal-title":"J Reprod Immunol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jri.2012.01.006","article-title":"The predominance of Th17 lymphocytes and decreased number and function of Treg cells in preeclampsia","volume":"93","author":"Darmochwal-Kolarz D","year":"2012","unstructured":"Darmochwal-Kolarz D, Kludka-Sternik M, Tabarkiewicz J, Kolarz B, Rolinski J, Leszczynska-Gorzelak B, Oleszczuk J. The predominance of Th17 lymphocytes and decreased number and function of Treg cells in preeclampsia. J Reprod Immunol. 2012, 93:75-81. 10.1016\/j.jri.2012.01.006","journal-title":"J Reprod Immunol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/srep27683","article-title":"The PD-1\/PD-L1 inhibitory pathway is altered in pre-eclampsia and regulates T cell responses in pre-eclamptic rats","volume":"6","author":"Tian M","year":"2016","unstructured":"Tian M, Zhang Y, Liu Z, Sun G, Mor G, Liao A. The PD-1\/PD-L1 inhibitory pathway is altered in pre-eclampsia and regulates T cell responses in pre-eclamptic rats. Sci Rep. 2016, 6:1-14. 10.1038\/srep27683","journal-title":"Sci Rep"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S221340","article-title":"The role of PD-1\/PD-L1 axis in Treg development and function: implications for cancer immunotherapy","volume":"12","author":"Cai J","year":"2019","unstructured":"Cai J, Wang D, Zhang G, Guo X. The role of PD-1\/PD-L1 axis in Treg development and function: implications for cancer immunotherapy. Onco Targets Ther. 2019, 12:8437-45. 10.2147\/OTT.S221340","journal-title":"Onco Targets Ther"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003130","article-title":"The PDL1-PD1 axis converts human TH1 cells into regulatory T cells","volume":"3","author":"Amarnath S","year":"2011","unstructured":"Amarnath S, Mangus CW, Wang JC, et al.. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med. 2011, 3:111-20. 10.1126\/scitranslmed.3003130","journal-title":"Sci Transl Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.22034\/IJI.2019.80259","article-title":"Evaluation of exhausted regulatory T cells in preeclampsia","volume":"16","author":"Daraei N","year":"2019","unstructured":"Daraei N, Ghafourian M, Ghadiri A, Amari A, Najafian M, Rokhafrooz S. Evaluation of exhausted regulatory T cells in preeclampsia. Iran J Immunol. 2019, 16:163-9. 10.22034\/IJI.2019.80259","journal-title":"Iran J Immunol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100262","article-title":"Immune checkpoint inhibitor administration during pregnancy: a case series","volume":"6","author":"Andrikopoulou A","year":"2021","unstructured":"Andrikopoulou A, Korakiti AM, Apostolidou K, Dimopoulos MA, Zagouri F. Immune checkpoint inhibitor administration during pregnancy: a case series. ESMO Open. 2021, 6:62. 10.1016\/j.esmoop.2021.100262","journal-title":"ESMO Open"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.12.015","article-title":"TGFb1 suppresses the activation of distinct dNK subpopulations in preeclampsia","volume":"39","author":"Zhang J","year":"2019","unstructured":"Zhang J, Dunk CE, Shynlova O, Caniggia I, Lye SJ. TGFb1 suppresses the activation of distinct dNK subpopulations in preeclampsia. EBioMedicine. 2019, 39:531-9. 10.1016\/j.ebiom.2018.12.015","journal-title":"EBioMedicine"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jri.2008.08.001","article-title":"Platelet aggregation and TGF-beta(1) plasma levels in pregnant women with preeclampsia","volume":"79","author":"Pera\u00e7oli MT","year":"2008","unstructured":"Pera\u00e7oli MT, Menegon FT, Borges VT, de Ara\u00fajo Costa RA, Thomazini-Santos IA, Pera\u00e7oli JC. Platelet aggregation and TGF-beta(1) plasma levels in pregnant women with preeclampsia. J Reprod Immunol. 2008, 79:79-84. 10.1016\/j.jri.2008.08.001","journal-title":"J Reprod Immunol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s43032-022-01156-x","article-title":"Circulating transforming growth factor-\u03b21 levels in preeclamptic women: a meta-analysis","volume":"30","author":"Wang X","year":"2023","unstructured":"Wang X, Wang T, Wang J, Niu X, Wang K, Hao Z, Gao H. Circulating transforming growth factor-\u03b21 levels in preeclamptic women: a meta-analysis. Reprod Sci. 2023, 30:1952-64. 10.1007\/s43032-022-01156-x","journal-title":"Reprod Sci"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2017.11.008","article-title":"Fibrosis in preeclamptic placentas is associated with stromal fibroblasts activated by the transforming growth factor-\u03b21 signaling pathway","volume":"188","author":"Ohmaru-Nakanishi T","year":"2018","unstructured":"Ohmaru-Nakanishi T, Asanoma K, Fujikawa M, et al.. Fibrosis in preeclamptic placentas is associated with stromal fibroblasts activated by the transforming growth factor-\u03b21 signaling pathway. Am J Pathol. 2018, 188:683-95. 10.1016\/j.ajpath.2017.11.008","journal-title":"Am J Pathol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.18585\/inabj.v9i1.310","article-title":"Comparison of transforming growth factor-beta 1 concentration in preeclampsia and normal pregnancy women","volume":"1","author":"Yusrawati Y","year":"2017","unstructured":"Yusrawati Y, Aidina D, Yerizel E. Comparison of transforming growth factor-beta 1 concentration in preeclampsia and normal pregnancy women. Indones Biomed J. 2017, 1:49. 10.18585\/inabj.v9i1.310","journal-title":"Indones Biomed J"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0412.2002.810214.x","article-title":"Transforming growth factor-beta 1 serum levels in pregnancy and pre-eclampsia","volume":"81","author":"Huber A","year":"2002","unstructured":"Huber A, Hefler L, Tempfer C, Zeisler H, Lebrecht A, Husslein P. Transforming growth factor-beta 1 serum levels in pregnancy and pre-eclampsia. Acta Obstet Gynecol Scand. 2002, 81:168-71. 10.1034\/j.1600-0412.2002.810214.x","journal-title":"Acta Obstet Gynecol Scand"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2005.11.023","article-title":"Transforming growth factor beta-1 influence on fetal allografts during pregnancy","volume":"37","author":"Ayatollahi M","year":"2005","unstructured":"Ayatollahi M, Geramizadeh B, Samsami A. Transforming growth factor beta-1 influence on fetal allografts during pregnancy. Transplant Proc. 2005, 37:4603-4. 10.1016\/j.transproceed.2005.11.023","journal-title":"Transplant Proc"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097632","article-title":"Soluble endoglin, transforming growth factor-beta 1 and soluble tumor necrosis factor alpha receptors in different clinical manifestations of preeclampsia","volume":"9","author":"Perucci LO","year":"2014","unstructured":"Perucci LO, Gomes KB, Freitas LG, et al.. Soluble endoglin, transforming growth factor-beta 1 and soluble tumor necrosis factor alpha receptors in different clinical manifestations of preeclampsia. PLoS One. 2014, 9:32. 10.1371\/journal.pone.0097632","journal-title":"PLoS One"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24097797","article-title":"Enhancing regulatory T cells to treat inflammatory and autoimmune diseases","volume":"24","author":"Fiyouzi T","year":"2023","unstructured":"Fiyouzi T, Pelaez-Prestel HF, Reyes-Manzanas R, Lafuente EM, Reche PA. Enhancing regulatory T cells to treat inflammatory and autoimmune diseases. Int J Mol Sci. 2023, 24:97. 10.3390\/ijms24097797","journal-title":"Int J Mol Sci"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70113-X","article-title":"Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial","volume":"1","author":"Hartemann A","year":"2013","unstructured":"Hartemann A, Bensimon G, Payan CA, et al.. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013, 1:295-305. 10.1016\/S2213-8587(13)70113-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005265","article-title":"Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease","volume":"5","author":"Matsuoka K","year":"2013","unstructured":"Matsuoka K, Koreth J, Kim HT, et al.. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013, 5:179. 10.1126\/scitranslmed.3005265","journal-title":"Sci Transl Med"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He J","year":"2016","unstructured":"He J, Zhang X, Wei Y, et al.. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016, 22:991-3. 10.1038\/nm.4148","journal-title":"Nat Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00887-2","article-title":"Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"7","author":"Zhang X","year":"2022","unstructured":"Zhang X, Miao M, Zhang R, et al.. Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther. 2022, 7:67. 10.1038\/s41392-022-00887-2","journal-title":"Signal Transduct Target Ther"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202413","article-title":"Self-specific memory regulatory T cells protect embryos at implantation in mice","volume":"191","author":"Chen T","year":"2013","unstructured":"Chen T, Darrasse-J\u00e8ze G, Bergot AS, et al.. Self-specific memory regulatory T cells protect embryos at implantation in mice. J Immunol. 2013, 191:2273-81. 10.4049\/jimmunol.1202413","journal-title":"J Immunol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2015.1037282","article-title":"The therapeutic potential of regulatory T cells for the treatment of autoimmune disease","volume":"19","author":"Bluestone JA","year":"2015","unstructured":"Bluestone JA, Trotta E, Xu D. The therapeutic potential of regulatory T cells for the treatment of autoimmune disease. Expert Opin Ther Targets. 2015, 19:1091-103. 10.1517\/14728222.2015.1037282","journal-title":"Expert Opin Ther Targets"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00478","article-title":"Therapeutic potential of regulatory T cells in preeclampsia-opportunities and challenges","volume":"10","author":"Robertson SA","year":"2019","unstructured":"Robertson SA, Green ES, Care AS, et al.. Therapeutic potential of regulatory T cells in preeclampsia-opportunities and challenges. Front Immunol. 2019, 10:478. 10.3389\/fimmu.2019.00478","journal-title":"Front Immunol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.15698\/cst2019.10.201","article-title":"Inflammation induced PD-L1-specific T cells","volume":"3","author":"Munir S","year":"2019","unstructured":"Munir S, Lundsager MT, J\u00f8rgensen MA, et al.. Inflammation induced PD-L1-specific T cells. Cell Stress. 2019, 3:319-27. 10.15698\/cst2019.10.201","journal-title":"Cell Stress"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgad072","article-title":"Interplay between inflammasomes and PD-1\/PD-L1 and their implications in cancer immunotherapy","volume":"44","author":"Jiao Z","year":"2023","unstructured":"Jiao Z, Zhang J. Interplay between inflammasomes and PD-1\/PD-L1 and their implications in cancer immunotherapy. Carcinogenesis. 2023, 44:795-808. 10.1093\/carcin\/bgad072","journal-title":"Carcinogenesis"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000863","article-title":"Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours","volume":"5","author":"Mair MJ","year":"2020","unstructured":"Mair MJ, Pajenda S, Ilhan-Mutlu A, et al.. Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours. ESMO Open. 2020, 5:63. 10.1136\/esmoopen-2020-000863","journal-title":"ESMO Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/287055-maternal-soluble-programmed-death-ligand-1-spd-l1-and-t-regulatory-cells-tregs-alteration-in-preeclampsia-a-cross-sectional-study-from-eastern-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T06:01:11Z","timestamp":1724738471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/287055-maternal-soluble-programmed-death-ligand-1-spd-l1-and-t-regulatory-cells-tregs-alteration-in-preeclampsia-a-cross-sectional-study-from-eastern-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":61,"URL":"https:\/\/doi.org\/10.7759\/cureus.67877","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,26]]}}}